medigraphic.com
ISSN 1561-3062 (Electronic)

2016, Number 3

<< Back Next >>

Revista Cubana de Obstetricia y Ginecología 2016; 42 (3)

Obstetrical antiphospholipid antibody syndrome in a case series in Cuba

Reyes LGA, Guibert TM, Álvarez VRR, Núñez HNJ, Vasallo PR

Language: Spanish
References: 31
Page: 344-353
PDF size: 113.93 Kb.


ABSTRACT

Introduction: antiphospholipid antibody syndrome (APS) is an acquired prothrombotic state characterized by the presence of antiphospholipid antibodies in patients with venous or arterial thrombosis and increased morbidity during pregnancy.
Objectives: describe the main clinical and epidemiological features of the syndrome during pregnancy as well as its perinatal outcomes.
Methods: a descriptive analytical study was conducted of a series of patients with antiphospholipid antibody syndrome and pregnancy at the Center for Medical Surgical Research and the National Rheumatology Center in Havana, Cuba. The study series was composed of 188 women. Examination was performed of the medical records of pregnant women either hospitalized or attending outpatient consultation at the two institutions who had been diagnosed with the syndrome as a primary or a secondary condition. A database was developed with epidemiological variables such as characteristics of the pregnancy and maternal fetal outcome.
Results: of the total patients studied in the series, 32 had thrombosis with obstetric morbidity. Primary antiphospholipid antibody syndrome was diagnosed in six patients, whereas secondary APS was diagnosed in 26 (17.5%). Mean age was 27 years. With respect to skin color, six out of every ten patients were white, and the rest were either brown or black. There were 81 pregnancies in the series, i.e. 2.53 patients / pregnancy, with 76% live births, 18% spontaneous abortions and 5% fetal deaths. 16% had a preterm delivery and 10% developed preeclampsia. There were no maternal deaths.
Conclusions: pregnancy in patients with antiphospholipid antibody syndrome is highly risky, with increased maternal and fetal morbidity and mortality.


REFERENCES

  1. Boffa MC, Boinot C, De Carolis S, Rovere-Querini P, Aurousseau MH, AllegriF, et al. Laboratory criteria of the obstetrical antiphospholipid syndrome. Data from a multicenter prospective European women cohort. Thromb Haemost. 2009;102:25-8.

  2. Di Simone N, Luigi MP, Marco D, Fiorella DN, Silvia D, Clara DM, et al. Pregnancy complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature. Ann NY Acad SCI. 2007;1108:505-14.

  3. Greaves M, Cohen H, Machin SJ, Makie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Hematol. 2000;109:704-15.

  4. Yamaguchi Y, Seta N, Kaburaki J, Kobayashi K, Matsuura E, Kuwana M. Excessive exposure to anionic surfacecs maintain antibody response to B2-Glicoprotein-1in patients with antiphospholipids syndrome. Blood. 2007;110:4312-8.

  5. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on a update of the classification criteria for definitive antiphospholipid syndrome. J ThrombHaemost. 2006;4:295-306.

  6. Misasi R, Capozzi A, Longo A, Recalchi S, Lococo E, Alessandri C, et al. New antigenic targets and methodological approaches for refining laboratory diagnosis of antiphosphoplipid syndrome. Inmunol Res. 2015. [citado 10 de septiembre 2013].Disponible en: http://dx.doi.org/10.1155/2015/858542

  7. Levy RA, Cunha Dos Santos F, de Jesús GR, de JesúsNR. Antiphospholipid antibodies and antiphospholipid syndrome during pregnancy: Diagnostic Concepts. Front Inmunology. 2015;6:205.

  8. Reyes Llerena GA, Gil A, Guibert Toledano M, Penedo-Coello A, Pérez Rodríguez A, Báez Dueñas RM, et al. Community based study to estimate prevalence and burden of illness rheumatic diseases in Cuba. A COPCORD study. JCR: Journal Clinical Rheumatology. 2009;15(2):51-5.

  9. Guibert Toledano ZM, Reyes Llerena Gil A, Rigñack Ramírez L, García C, Acosta Lapera D, Salgado Galloso SB. Embarazo y puerperio en el lupus eritematoso sistémico. Actualización. Rev. Cubana de Reumatología. 2013;15(2):71-5.

  10. Reyes Llerena Gil A, Guibert Toledano M, Vasallo Prieto R, López Mantecón AM, López Aguilera IR, Delgado Ferreiro I. Estudio analítico y actualización temática de una serie de pacientes en Cuba con Lupus y embarazo. Rev Cubana de Ginecología Obstetricia. 2009;13(3):4-9.

  11. Gómez-Puerta JA, Sanin-Blair J, Galarza-Maldonado C. Pregnancy and catastrophic antiphospholipid syndrome. Clin Rev Allergy-Imunol. 2009;36:85-90.

  12. Tufano A, Coppola A, Maruotti GM, Martinelli P, Cerbone AM, Di Minno G. HELLP Syndrome and its relation with the antiphospholipid syndrome. Blood Transfus. 2014;12(1):114-8.

  13. Franco JS, Molano González N, Rodríguez Jiménez M, Acosta Ampudia Y. The coexistence of antiphospholipid syndrome and systemic lupus erithematosus in Colombians. Plos One. 2014;9(10).

  14. Kovács M, Hartwig M, Aleksza M, Tihanyi M, Nagy T, Vajda G, et al. Antiphospholipid antibodies in relation to sterility/infertility. Hum Immunol. 2012;73(7):726-31.

  15. Hanouna G, Morel N, Le ThiHuong D, Josselin L, Vauthier-Brouzes D, Saadoun D, et al. Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. Rheumatology. (Oxford) 2013;52(9):1635-41.

  16. Aliojotas-Reig J. Treatment of refractory obstetric antiphospholipid syndrome: the state or art and the new trends in the therapeutic management. Lupus. 2013;22(1):6-17.

  17. Abisror N, Mekinian A, Lachssinne E, Nicaise-Roland P, Pontual LD, Chollet- Martin S, et al. Autism spectrum disorders in babies born to mothers with antiphospholipid syndrome. Semin Arthritis Rheum. 2013;172(13):149-2.

  18. Boffa MC, Aurousseau MH, Lachassinne E, Dauphin H, Fain O, Le Toumelin P. European Register of babies born to mothers with antiphospholipid syndrome. Lupus. 2004;13(9):713-7.

  19. Mekinian A, Lachassinne E, Nicaise-Roland P, Carbillon L, Motta M, Vicaut, et al. European Registry of babies born to mothers with antiphospholipids syndrome. Ann Rheum Dis. 2013;72(2):217-22.

  20. Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA. Obstetrical complications associate with abnormal maternal serum markers analytes. J Obstet Gynaecol Can. 2008;(10):918-49.

  21. Ruiz Iraztorza G, Crowthwe M, Branch Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498-509.

  22. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT. Anthiphospholipid Syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patient. Arthritis Rheum. 2002;46:1019-27.

  23. Lugones Botell M, Ramírez Bermúdez M, López Jl. Síndrome antifosfolipidico. Algunos aspectos de interés para nuestra especialidad. Rev. Cubana Obstet Ginecol. 2006;32(3):3.

  24. Le thiHuong D, Wechsler B, Vauthier-Brouzes D, Duhaut P, Costedoat N. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemics lupus erythematosus and or the antiphospholipid syndrome. Rheumatology (Oxford). 2006;45(3):332-8.

  25. Bats AS, Lejeune V, Cynober E, Safar E, González M, Milliez J, et al. Antiphospholipid syndrome and second-or trhirdthrimester fetal death: follow-up in the next pregnancy. Eur J Obstet GynecolReprod Biol. 2004;114(2):125-9.

  26. De Stefano V, Martinelli J, Rossi E, Battaglioli T, MannuccioMannucci P, Leone G. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br. J Haematol. 2006;135(3):386-91.

  27. Marchetti T, Cohén M, de Moer loose P. Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications. Clin Dev Immunol. 2013;2013:159124.doi:10.1155/2013/159124.

  28. Ronald H, Derksen RHWM, Khamashta MA, Branch DW. Management of the obstetric antiphospohilipid syndrome. Arth Rheum. 2004;50:1028-39.

  29. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic diseases: American College of chest physicians evidence-based clinical practice guidelines (8th Ed). Chest. 2008 Jun;133(6 Suppl):454S-545S.

  30. Laskin CA, Spitzer KA, Clark CA, Crowtheer MR, Ginsberg JS, Hawker GA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the ramdomized, controlled Hep - ASA trial. J Rheumatol. 2009;36(2):279-87.

  31. Xiao J, Xiong J, Zhu F. Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome. ExpTher Med. 2013;5(1):287-91.




2020     |     www.medigraphic.com